Purchase your raffle tickets NOW! Early-bird drawing in 1 week!
CASH FOR THE HOLIDAYS 
LFNC's Newest Charity Raffle!
November 15, 2011
Early-bird Drawing
December 15, 2011 Final Drawing Details |
THE HANGOUT
A safe and supportive group environment where young lupus patients and their friends come together to share their concerns and hopes, as well as their personal experiences in managing their disease and symptoms. Next meeting is Saturday, November 19, 2011. For more info, please call Sandra at (510) 909-8485 or email her at minilopez04@yahoo.com |
Information contained in this e-Newsletter should not be considered a substitute for professional diagnosis, treatment or management of S.L.E. and symptoms by a physician.
Missed a previous issue of this e-Newsletter?
You can now view our ARCHIVES.
Editor: Rene Astudillo
Editorial Assistant: Spandan Chakrabarti |
|
LFNC's Social Media Program is party funded through a generous grant from
|
|
|
|
Experimental Drug LUPUZOR Gets Green Light for Phase III Clinical Trial!
The U.S. Food and Drug Administration (FDA) has given the green light to the U.K. drug discovery company ImmuPharma PLC to begin Phase III clinical trials for its experimental lupus drug Lupuzor.
FDA also granted Lupuzor a "fast track designation." A fast track designation is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions that demonstrate the potential to address unmet medical needs.
Lupuzor™ (previously known as IPP-201101) has a novel mechanism of action aimed at modulating the body's immune system so it does not attack healthy cells without causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
A Phase III clinical trial is the final stage prior to a drug company submitting a New Drug Application to the FDA. Under Phase III, an experimental drug is tested in a large group of people -- several hundred to several thousands -- to determine the drug's effectiveness, side effects, benefits , risks and safety. It is also compared to commonly used treatment.
ImmuPharma is currently in talks with pharmaceutical companies regarding a potential licensing deal for the lupus treatment.
Earlier this year, the FDA approved Benlysta (Human Genome Sciences/GlaxoSmithKline) for the treatment of lupus, the first such drug approved in more than 50 years.
Like Benlysta, Lupuzor is a biologic drug. Biologics are treatments created from living cells -- as opposed to chemicals like in pills -- and are usually administered intravenously.
Read MORE. |
The Lupus Research Institute and its National Coalition (including LFNC), are asking for public support for health coverage of Benlysta in the U.K.
The United Kingdom's (UK) National Institute for Health and Clinical Excellence (NICE) recently released its preliminary recommendation to NOT cover the cost of Benlysta(R) through the National Health Service.Their preliminary recommendation could have a devastating international impact on the survival of this important new treatment, and it may have a chilling effect on the future development of new lupus drugs thereby denying physicians and patients appropriate treatment options.
Please sign the petition to enable as many lupus patients in the U.K. to gain access to this lupus treatment. |
LFNC BROWN BAG SESSION ON BENLYSTA DECEMBER 1, 2011
As part of its Brown Bag Educational Series, LFNC is holding a brown bag session to discuss the new drug Benlysta. Guest presenter is Dana Hawkes, RN, clinical nurse educator, Immunology, with Human Genome Sciences, Inc.
The session will be held on Thursday, December 1, 2011, from 11:30 a.m. to 1:00 p.m. at the LFNC Office located at 2635 N. First Street, Suite 211, San Jose, CA 95134.
Due to limited space, REGISTRATION IS REQUIRED.
|
|
|
|
|
LFNC is an active partner in
|
|
|
LUPUS FOUNDATION OF NORTHERN CALIFORNIA
